X-Energy enters July in a difficult spot — down 32% over the past month and 13% on the week, yet carrying a wall of analyst price targets that implies the stock is deeply undervalued at $18.36.
The Street's bullish framing is the central tension here. Coverage launched in mid-May with a cluster of initiations, nearly all positive: JPMorgan, Morgan Stanley, TD Cowen, Cantor Fitzgerald, and Guggenheim all came out with Buy-equivalent ratings and targets ranging from $35 to $57. Only Jefferies held back with a Hold at $28. The mean target now sits around $37.85 — more than double the current price. That gap is not a rounding error; it reflects either genuine long-term conviction in the Xe-100 reactor program or a cohort of freshly-initiated analysts yet to revisit their models after a brutal earnings print. UBS, which initiated at $40 in May, trimmed its target to $34 on July 1 while keeping its Buy — a signal of conviction maintained but expectations revised down. The bull case rests on advanced nuclear as a structural theme: utilities needing firm low-carbon power, data center operators hunting reliable baseload, and the Xe-100's small modular reactor design as a commercialisation path that could look very different in five years. Bears point to the same calendar — the company is pre-revenue, burning cash, and dependent on regulatory and demonstration milestones that carry real execution risk.
The earnings history sharpens that bear case considerably. X-Energy's June 4 Q1 report triggered an 18.5% single-day decline, with the stock continuing to fall another 10 points over the following week — a combined five-day move of nearly 29%. That is the kind of reaction that tells you the market treats each update as a binary catalyst, not a routine quarter. The next earnings event is scheduled for early September, giving traders roughly two months of positioning runway before the next event-driven test.
Options positioning has turned more defensive than it was six weeks ago. The put/call ratio is running at 0.87, about one standard deviation above its 20-day average of 0.73. That is a meaningful shift — in early June the PCR was sitting below 0.60, reflecting relatively relaxed hedging. The move toward more put coverage over the past two weeks tracks the price decline almost exactly, and the PCR has been consistently elevated since mid-June. It has not hit an extreme — the 52-week high is 1.67 — but the direction of travel is clear.
On the lending side, short interest has been a consistent feature of this name. Prior coverage noted a meaningful portion of the float in skeptical hands, and that dynamic persists. For a pre-revenue nuclear developer in a sentiment-driven sector, a sizeable short base is structurally expected: the thesis takes years to play out, and borrowed shares are a natural hedge against that timeline uncertainty. There is no sign of a squeeze setup — the availability picture does not suggest lending supply is being tested — but neither is the short base unwinding.
Valuation multiples tell a largely negative story on trailing figures, as you would expect from a company with no revenue. The price-to-book ratio has compressed sharply, falling roughly 2.3 points over the past 30 days as the stock re-rated lower. The EV/EBITDA figure is negative, reflecting operating losses. What matters for XE's valuation story is therefore not the multiples themselves but the pace at which the regulatory and commercial pipeline progresses — specifically any updates on the Xe-100 design approval and announced utility partnerships. The ORTEX stock score, last measured at 62.8 in late April, was trending up from a low base; whether that momentum has survived the June selloff will be worth watching when the next reading arrives.
The next hard catalyst is September earnings, but the intervening period will trade on regulatory newsflow around the Xe-100 and any partnership or contracting announcements — the same binary variables that defined the May-to-June round trip.
See the live data behind this article on ORTEX.
Open XE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
